Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis

JACC: Cardiovascular Imaging

Volumn 10, Issue 4, 2017, Pages 411-420

  Coleman, G Cameron ^a   Shaw, Peter W ^a   Balfour, Pelbreton C ^a   Gonzalez, Jorge A ^a   Kramer, Christopher M ^a,b   Patel, Amit R ^c   Salerno, Michael ^a,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d University of Virginia   (United States)

Author keywords

cardiac magnetic resonance; cardiac sarcoid; cardiovascular outcomes; late gadolinium enhancement

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM;

ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL (TOPIC); FOLLOW UP; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MYOCARDIAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; SARCOIDOSIS; SCAR FORMATION; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; ADULT; AGED; CARDIAC MUSCLE; CARDIOMYOPATHIES; CHI SQUARE DISTRIBUTION; CICATRIX; DIAGNOSTIC IMAGING; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ODDS RATIO; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; TIME FACTOR;

ADULT; AGED; CARDIOMYOPATHIES; CHI-SQUARE DISTRIBUTION; CICATRIX; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SARCOIDOSIS; TIME FACTORS;

EID: 85002602600     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2016.05.009     Document Type: Article

References (45)

1. 1 Statement on sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999. Am J Respir Crit Care Med 160 (1999), 736–755.
2. 2 Yazaki, Y., Isobe, M., Hiroe, M., et al., for the Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88 (2001), 1006–1010.
3. 3 Kim, J.S., Judson, M.A., Donnino, R., et al. Cardiac sarcoidosis. Am Heart J 157 (2009), 9–21.
4. 4 Roberts, W.C., McAllister, H.A. Jr., Ferrans, V.J., Sarcoidosis of the heart: A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 63 (1977), 86–108.
5. 5 Smedema, J.P., Snoep, G., van Kroonenburgh, M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 (2005), 1683–1690.
6. 6 Patel, M.R., Cawley, P.J., Heitner, J.F., et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 120 (2009), 1969–1977.
7. 7 Kumar, A., Patton, D.J., Friedrich, M.G., The emerging clinical role of cardiovascular magnetic resonance imaging. Can J Cardiol 26 (2010), 313–322.
8. 8 Greulich, S., Deluigi, C.C., Gloekler, S., et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. J Am Coll Cardiol Img 6 (2013), 501–511.
9. 9 Nadel, J., Lancefield, T., Voskoboinik, A., Taylor, A.J., Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging 16 (2015), 634–641.
10. 10 Nagai, T., Kohsaka, S., Okuda, S., Anzai, T., Asano, K., Fukuda, K., Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 146 (2014), 1064–1072.
11. 11 Green, J.J., Berger, J.S., Kramer, C.M., Salerno, M., Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol Img 5 (2012), 370–377.
12. 12 Kuruvilla, S., Adenaw, N., Katwal, A.B., Lipinski, M.J., Kramer, C.M., Salerno, M., Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging 7 (2014), 250–258.
13. 13 Hamirani, Y.S., Wong, A., Kramer, C.M., Salerno, M., Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol Img 7 (2014), 940–952.
14. 14 Stroup, D.F., Berlin, J.A., Morton, S.C., et al., for the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283 (2000), 2008–2012.
15. 15 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269 W64.
16. 16 Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed December 9, 2015.
17. 17 Studies with zero-cell counts (section 16.9.2). In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: http://handbook.cochrane.org/. Accessed May 17, 2016.
18. 18 Patel, A.R., Klein, M.R., Chandra, S., et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail 13 (2011), 1231–1237.
19. 18F-fluorodoexyglucose positron emission tomography?. Circ Cardiovasc Imaging 6 (2013), 617–626.
20. 20 Panda, S., Kaur, D., Lalukota, K., Sundar, G., Pavri, B.B., Narasimhan, C., Pleomorphism during ventricular tachycardia: a distinguishing feature between cardiac sarcoidosis and idiopathic VT. Pacing Clin Electrophysiol 38 (2015), 694–699.
21. 21 Ahmadian, A., Brogan, A., Berman, J., et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 21 (2014), 925–939.
22. 22 Cheong, B.Y., Muthupillai, R., Nemeth, M., et al. The utility of delayed-enhancement magnetic resonance imaging for identifying nonischemic myocardial fibrosis in asymptomatic patients with biopsy-proven systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 26 (2009), 39–46.
23. 23 Kron, J., Sauer, W., Mueller, G., et al. Outcomes of patients with definite and suspected isolated cardiac sarcoidosis treated with an implantable cardiac defibrillator. J Interv Card Electrophysiol 43 (2015), 55–64.
24. 24 Mehta, D., Mori, N., Goldbarg, S.H., Lubitz, S., Wisnivesky, J.P., Teirstein, A., Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 4 (2011), 43–48.
25. 25 Mehta, D., Lubitz, S.A., Frankel, Z., et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 133 (2008), 1426–1435.
26. 26 Nery, P.B., Beanlands, R.S., Nair, G.M., et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 25 (2014), 875–881.
27. 27 Orii, M., Hirata, K., Tanimoto, T., et al. Comparison of cardiac MRI and 18F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complete heart block. Heart Rhythm 12 (2015), 2477–2485.
28. 28 Paz, Y.E., Bokhari, S., The role of F18-fluorodeoxyglucose positron emission tomography in identifying patients at high risk for lethal arrhythmias from cardiac sarcoidosis and the use of serial scanning to guide therapy. Int J Cardiovasc Imaging 30 (2014), 431–438.
29. 29 Smedema, J.P., Snoep, G., van Kroonenburgh, M.P., et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 128 (2005), 1629–1637.
30. 30 Tezuka, D., Terashima, M., Kato, Y., et al. Clinical characteristics of definite or suspected isolated cardiac sarcoidosis: application of cardiac magnetic resonance imaging and 18F-fluoro-2-deoxyglucose positron-emission tomography/computerized tomography. J Card Fail 21 (2015), 313–322.
31. 31 Yokoyama, R., Miyagawa, M., Okayama, H., et al. Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis. Int J Cardiol 195 (2015), 180–187.
32. 32 Ise, T., Hasegawa, T., Morita, Y., et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 100 (2014), 1165–1172.
33. 33 Betensky, B.P., Tschabrunn, C.M., Zado, E.S., et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 9 (2012), 884–891.
34. 34 Blankstein, R., Osborne, M., Naya, M., et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 63 (2014), 329–336.
35. 35 Crawford, T., Mueller, G., Sarsam, S., et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol 7 (2014), 1109–1115.
36. 36 Murtagh, G., Laffin, L.J., Beshai, J.F., et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging, 9, 2016, e003738.
37. 37 Poyhonen, P., Holmstrom, M., Kivisto, S., Hanninen, H., Late gadolinium enhancement on CMR and sustained ventricular tachycardia predict severe cardiac inflammation. Acta Cardiol 69 (2014), 637–647.
38. 38 Shafee, M.A., Fukuda, K., Wakayama, Y., et al. Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. J Cardiol 60 (2012), 448–453.
39. 39 Watanabe, E., Kimura, F., Nakajima, T., et al. Late gadolinium enhancement in cardiac sarcoidosis: characteristic magnetic resonance findings and relationship with left ventricular function. J Thorac Imaging 28 (2013), 60–66.
40. 40 Smedema, J.P., Snoep, G., van Kroonenburgh, M.P., et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 128 (2005), 30–35.
41. 41 Vignaux, O., Dhote, R., Duboc, D., et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr 26 (2002), 762–767.
42. 42 Birnie, D.H., Sauer, W.H., Bogun, F., et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11 (2014), 1305–1323.
43. 43 Kron, J., Sauer, W., Schuller, J., et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 15 (2013), 347–354.
44. 44 Salerno, M., Kramer, C.M., Advances in parametric mapping with CMR imaging. J Am Coll Cardiol Img 6 (2013), 806–822.
45. 45 Crouser, E.D., Ono, C., Tran, T., He, X., Raman, S.V., Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med 189 (2014), 109–112.